PALISADE CAPITAL MANAGEMENT, LP - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 41 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
PALISADE CAPITAL MANAGEMENT, LP ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2018$900,000
-8.6%
975,0000.0%0.03%
+22.2%
Q3 2018$985,000
-24.1%
975,000
-33.9%
0.03%
-28.9%
Q2 2018$1,297,000
+8.8%
1,476,0000.0%0.04%
-5.0%
Q1 2018$1,192,000
+0.8%
1,476,0000.0%0.04%0.0%
Q4 2017$1,183,000
+2.4%
1,476,0000.0%0.04%
-2.4%
Q3 2017$1,155,000
-19.7%
1,476,0000.0%0.04%
-24.1%
Q2 2017$1,439,000
+3.9%
1,476,0000.0%0.05%
+1.9%
Q1 2017$1,385,000
+4.4%
1,476,0000.0%0.05%
+6.0%
Q4 2016$1,326,000
-19.9%
1,476,000
-0.2%
0.05%
-15.3%
Q3 2016$1,656,0001,479,0000.06%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2017
NameSharesValueWeighting ↓
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$56,098,0001.12%
L & S Advisors Inc 795,000$767,0000.14%
OAKTREE CAPITAL MANAGEMENT LP 9,964,000$9,690,0000.11%
WEDBUSH SECURITIES INC 13,000$1,251,0000.07%
Kohlberg Kravis Roberts & Co. L.P. 3,163,000$3,076,0000.06%
ZAZOVE ASSOCIATES LLC 246,000$240,0000.02%
Balboa Wealth Partners 21,000$200.01%
Russell Investments Group, Ltd. 1,910,000$1,875,0000.00%
GAMCO INVESTORS, INC. ET AL 250,000$244,0000.00%
Regal Investment Advisors LLC 20,000$19,0000.00%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders